PPT-Btk inhibition in Mantle cell Lymphoma & CLL

Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth DISCLOSURES OF COMMERCIAL SUPPORT Name of Company Research support. Lymphoma is divided into two major categories Hodgkin lymphoma HL and nonHodgkin lymphoma NHL Mantle cell lymphoma MCL is one of about 70 di64256erent subtypes of NHL Lymphoma may arise in any one of three types of lymphocytes B lymphocytes B cells Impact . on t. iming . of . therapy. Nicholas Chiorazzi. The Feinstein Institute for Medical Research. North Shore – LIJ Health System. Manhasset, NY. At all points in time, CLL clones are heterogeneous based on a number of criteria. Ibrutinib. Sensitivity and Resistance in CLL. Y. Lynn Wang, MD, PhD, FCAP. Dept. of Pathology. University of Chicago. October 24, 2014. Outline. Ibrutinib. targets . in vivo CLL proliferation through . Spring 2010. Clinical history. A 62 year old man presents to his primary care physician with lymphadenopathy. . A CBC demonstrates the following: . WBC 20.73 thousand cell/microliter . 12% neutrophils. (blind, torture, kill). By Maddie Gross. “I actually may be possessed with demons, I was dropped on my head as a kid.” ~ Dennis Rader . . Background . Born in Pittsburg, Kansas. Grew up in Wichita Kansas. is the most common type of . leukemia. . . CLL involves a particular subtype of white blood cells, which is a . lymphocyte. called a . B cell. . . . The . definition of CLL includes >5000 CLL-phenotype . and their . precursor . cells. .  The name often refers to just the . cancerous. . ones . rather than all such . tumors. .. Many lymphomas are known to be due to specific genetic mutations.. 3. rd. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu.edu). Disclosures. Speakers Bureau: GSK, . Millenium. , . Cephalon. CLL: Pertinent Topics. ASH treatment updates. James DF, et al. ASH 2011. Abstract 291.. Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP Clinical Pharmacy Specialist, Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Panelist Matthew Snyder, PharmD, BCOP MODERATOR : DR. GANAPULE . Definition . Lymphomas are malignant . tumours. of lymphoid tissue which give rise to solid tissue masses.. Heterogenous. group of disorders.. HODGKINS LYMPHOMA. NON-HODGKINS. Dr. Sanne Lugthart. (. Dr. Stephen Robinson). University Hospital Bristol. 20 June 2019. Scope Of Talk. Current CAR T products available for NHS patients. The CAR T pathway (up to re-infusion). Patients Cases. p. otential hotspot. p. otential hotspot. Based on illustration by . Lidunka. . Vočadlo. , University College London. We propose this scenario: . Layered Mantle Convection. Location of the boundary can be adjusted to suit different needs.. Dr Mona Yuklea. Hematology Department, Meir Hospital, 2019. CLL - incidence. The most common leukemia among adults in Western Countries. 4-6 cases /100000 person/year. At diagnosis. More than 70% of patients – older than 65 y.